Pharmaceutical practice of bevacizumab-induced refractory hypertension and proteinuria in a patient with advanced lung adenocarcinoma
10.12173/j.issn.1005-0698.202506035
- VernacularTitle:1例贝伐珠单抗致晚期肺腺癌患者难治性高血压和蛋白尿的药学实践
- Author:
Jiaju YAN
1
;
Yongyong YUAN
;
Meng LIU
Author Information
1. 六安市第二人民医院药学部(安徽 六安 237006)
- Publication Type:Journal Article
- Keywords:
Bevacizumab;
Lung adenocarcinoma;
Resistant hypertension;
Proteinuria;
Phamaceutical care
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(11):1335-1339
- CountryChina
- Language:Chinese
-
Abstract:
One patient with advanced lung adenocarcinoma developed refractory hypertension after 19 months of treatment with bevacizumab and afatinib,the clinical pharmacist analyzed the patient's medication,and consulted the relevant literature,considering that the patient's refractory hypertension was related to bevacizumab and sleep difficulties.Because of the patient's proteinuria and the fact that the patient's blood pressure was not controlled below 130/80 mmHg,it was recommended that bevacizumab should be suspended,and the doctor accepted the recommendation.Through multiple adjustments to the antihypertensive regimen(nifedipine controlled-release,sacubitril/valsartan,metoprolol,indapamide)and sleep improvement(mirtazapine,lorazepam).The patient's sleep duration was extended to 4-5 hours,blood pressure was controlled below 130/80 mmHg,and bevacizumab treatment was resumed.In this case,the clinical pharmacist participated in the patient's drug treatment process,assisted the doctor in the adjustment of the individualized treatment plan for special populations,and promoted the patient's rational drug use.
